You are here: Industry Insights > arthritis drug

News List

Roche’s arthritis drug shows effectiveness for ill patients in Covid-19 trial pharmaceutical-technology
November 23, 2020
The UK’s Imperial College London has reported that early data from the REMAP-CAP trial showed Roche’s arthritis drug, Actemra (tocilizumab), is expected to reduce deaths and time spent in intensive care in critically ill patients with severe Covid-19.
Experimental arthritis drug prevents stem cell transplant complication europeanpharmaceuticalreview
April 28, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants…
FDA advisors back Lilly/Incyte’s rheumatoid arthritis drug pharmatimes
April 25, 2018
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA).
Eli Lilly’s Arthritis Drug Gets Mixed Recommendation, But Reports Strong Quarter biospace
April 25, 2018
Last week, briefing documents related to the U.S. Food and Drug Administration (FDA)’s advisory committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis expressed safety concerns.
Lilly and Incyte's resubmission of arthritis drug data fails to assuage FDA concerns pharmafile
April 23, 2018
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib after the FDA raised concerns over its safety in a resubmission of data following rejection last year.
Lilly gets second shot at application for ‘blockbuster’ arthritis drug pharmafile
September 01, 2017
The FDA rejected the drug and asked Lilly for more data, after it pointed out instances of blood clotting in trial data
Arthritis drug may treat blood cancer patients expressbpd
August 07, 2017
University of Sheffield scientists discover drug which offers an affordable and effective treatment
FDA advisers reject J&J rheumatoid arthritis drug pharmaphorum
August 04, 2017
The chances of Johnson & Johnson’s rheumatoid arthritis drug sirukumab getting approved in the US look slim, after the FDA’s expert advisers raised concerns about its safety.
Arthritis Drug Shows Promise for Ulcerative Colitis drugs.com
May 04, 2017
A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.
Pfizer receive European approval for arthritis drug pharmafile
March 28, 2017
Following on from the positive opinion given to Xeljanz in January of this year, Pfizer’s drug has now been given European Commission marketing authorisation for treatment of moderate to severe active rheumatoid arthritis (RA).